• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

How does the TRS 2°P score relate to real-world patients?

作者信息

Bonaca Marc P, De Ferrari Gaetano M, Atar Dan, Bash Lori D, Lautsch Dominik, Bohula Erin A, Horack Martin, Brudi Philippe, Ferrieres Jean, Gitt Anselm K

机构信息

TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.

Department of Molecular Medicine University of Pavia, and Cardiac Intensive Care Unit and Laboratories for Experimental Cardiology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.

出版信息

Eur Heart J Cardiovasc Pharmacother. 2018 Apr 1;4(2):72-74. doi: 10.1093/ehjcvp/pvy004.

DOI:10.1093/ehjcvp/pvy004
PMID:29554293
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5939887/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/895e/5939887/6c846aee15b5/pvy004f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/895e/5939887/6c846aee15b5/pvy004f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/895e/5939887/6c846aee15b5/pvy004f1.jpg

相似文献

1
How does the TRS 2°P score relate to real-world patients?TRS 2°P评分与真实世界中的患者有怎样的关系？
Eur Heart J Cardiovasc Pharmacother. 2018 Apr 1;4(2):72-74. doi: 10.1093/ehjcvp/pvy004.
2
Aggressive lipid management in very elderly adults: less is more.高龄老年人积极的血脂管理：少即是多。
J Am Geriatr Soc. 2014 May;62(5):945-7. doi: 10.1111/jgs.12788_2. Epub 2014 May 6.
3
Niacin in cardiovascular patients receiving statins.接受他汀类药物治疗的心血管疾病患者中的烟酸
N Engl J Med. 2012 Mar 29;366(13):1255; author reply 1255-6. doi: 10.1056/NEJMc1200980.
4
Niacin at 56 years of age--time for an early retirement?56岁的烟酸——是提前退休的时候了？
N Engl J Med. 2011 Dec 15;365(24):2318-20. doi: 10.1056/NEJMe1112346. Epub 2011 Nov 15.
5
[Combination therapy of atherogenic dyslipidemias in women].[女性致动脉粥样硬化性血脂异常的联合治疗]
Kardiologiia. 2008;48(4):66-70.
6
Niacin's effect on cardiovascular risk: have we finally learned our lesson?
Cleve Clin J Med. 2014 May;81(5):275-7. doi: 10.3949/ccjm.81a.13067.
7
Options for the treatment of hyperlipidemia in Type 2 diabetes mellitus and hypothyroidism: lowering the cardiovascular risk.2型糖尿病合并甲状腺功能减退症患者高脂血症的治疗选择：降低心血管风险
Future Cardiol. 2011 Mar;7(2):137-44. doi: 10.2217/fca.10.126.
8
Lipid disorders in type 2 diabetes.2型糖尿病中的脂质紊乱
Endocrinol Nutr. 2009 Dec;56 Suppl 4:43-5.
9
Real-world use of PCSK9 inhibitors: A single-center experience.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂的真实世界应用：单中心经验
J Int Med Res. 2019 Jan;47(1):265-270. doi: 10.1177/0300060518800595. Epub 2018 Oct 3.
10
Statins in threatened stroke.
Stroke. 2003 Feb;34(2):351-3. doi: 10.1161/01.str.0000054260.05136.7d.

引用本文的文献

1
TIMI Risk Score for Secondary Prevention to Risk Stratify Chronic Coronary Syndrome Patients: External Validation Study.用于慢性冠状动脉综合征患者风险分层的二级预防TIMI风险评分：外部验证研究
Arq Bras Cardiol. 2025 Apr;122(5):e20240821. doi: 10.36660/abc.20240821.
2
Long-Term Risk Stratification of Patients Undergoing Coronary Angiography According to the Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention.根据心肌梗死溶栓治疗风险评分进行冠状动脉造影术后患者的长期风险分层。
J Am Heart Assoc. 2019 Jul 16;8(14):e012433. doi: 10.1161/JAHA.119.012433. Epub 2019 Jul 4.
3
Do acute coronary events affect lipid management and cholesterol goal attainment in Germany? : Results from the Dyslipidemia International study II.

本文引用的文献

1
Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II.稳定性或急性冠心病患者的胆固醇目标值达标和降脂治疗：来自血脂异常国际研究 II 的结果。
Atherosclerosis. 2017 Nov;266:158-166. doi: 10.1016/j.atherosclerosis.2017.08.013. Epub 2017 Aug 21.
2
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.PCSK9 抑制剂依洛尤单抗降低 LDL-胆固醇水平的临床疗效和安全性：FOURIER 试验的预先设定的次要分析。
Lancet. 2017 Oct 28;390(10106):1962-1971. doi: 10.1016/S0140-6736(17)32290-0. Epub 2017 Aug 28.
3
急性冠脉事件会影响德国的血脂管理及胆固醇目标达成情况吗？：血脂异常国际研究II的结果
Wien Klin Wochenschr. 2018 Dec;130(23-24):707-715. doi: 10.1007/s00508-018-1375-3. Epub 2018 Sep 3.
Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention.动脉粥样硬化血栓形成风险分层与依折麦布用于二级预防。
J Am Coll Cardiol. 2017 Feb 28;69(8):911-921. doi: 10.1016/j.jacc.2016.11.070.
4
New ESC/EACTS Guidelines for the management of atrial fibrillation.
Eur Heart J Cardiovasc Pharmacother. 2017 Apr 1;3(2):71-72. doi: 10.1093/ehjcvp/pvw038.
5
2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult.《2016年加拿大心血管学会成人血脂异常管理预防心血管疾病指南》
Can J Cardiol. 2016 Nov;32(11):1263-1282. doi: 10.1016/j.cjca.2016.07.510. Epub 2016 Jul 25.
6
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.2016年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动管理指南。
Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.
7
Treatment thresholds for stroke prevention in atrial fibrillation: observations on the CHA2DS2-VASc score.心房颤动患者卒中预防的治疗阈值：关于CHA2DS2-VASc评分的观察
Eur Heart J Cardiovasc Pharmacother. 2017 Jan;3(1):37-41. doi: 10.1093/ehjcvp/pvw022. Epub 2016 Aug 12.
8
Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.动脉粥样硬化血栓形成风险分层以及vorapaxar在稳定型缺血性心脏病和既往心肌梗死患者中的疗效与安全性
Circulation. 2016 Jul 26;134(4):304-13. doi: 10.1161/CIRCULATIONAHA.115.019861.
9
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.依折麦布联合他汀类药物治疗急性冠脉综合征。
N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.
10
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.全球、地区和国家按年龄、性别划分的 240 种死因的全死因和特定死因死亡率，1990-2013 年：2013 年全球疾病负担研究的系统分析。
Lancet. 2015 Jan 10;385(9963):117-71. doi: 10.1016/S0140-6736(14)61682-2. Epub 2014 Dec 18.